Category: Health Services, Science & Nature, Technology

Tags: Taletrectinib in India, Ibtrozi in India, ROS1 Positive NSCLC, Non Small Cell Lung Cancer, ROS1 Inhibitor, Targeted Cancer Therapy, oncology

Taletrectinib is a next-generation oral tyrosine kinase inhibitor (TKI) indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Designed to selectively target ROS1 gene rearrangements, taletrectinib offers a precision medicine approach for patients whose tumors are driven by this molecular alteration. It is available as 200 mg immediate-release capsules, with the recommended dosage and treatment duration determined according to the approved prescribing information and continued based on clinical response and tolerability.